Literature DB >> 8625235

Histologic changes in small cell lung carcinoma after treatment.

H Fushimi1, M Kikui, H Morino, S Yamamoto, R Tateishi, A Wada, K Aozasa, K Kotoh.   

Abstract

BACKGROUND: Small cell lung carcinoma (SCLC) has been divided into three subtypes: pure SCLC, mixed small cell/large cell carcinoma (mixed SC/LC), and combined SCLC. Patients with mixed SC/LC show a worse prognosis than those with pure SCLC.
METHODS: Persistence of histologic subtype in SCLC in the primary sites during the course of treatment or in the different organs at autopsy was examined. For this purpose, biopsy or cytologic specimens before chemotherapy, and autopsy specimens from 175 patients with SCLC were reviewed. They included 147 (84%) men and 28 (16%) women with an age range of 29-83 (median, 65) years.
RESULTS: The frequency of mixed SC/LC in the primary sites was statistically higher in autopsy (14.3%) than that in biopsy or cytology specimens (8.6%) (P < 0.05). At autopsy, involved organs were categorized into two groups according to frequency of appearance of mixed SC/LC, i.e., a higher frequency group, including the liver (31 of 85; 36.4%), adrenal gland (15 of 56; 26.8%), brain (6 of 9; 66.7%), and extrathoracic lymph nodes (17 of 59; 28.8%) and a lower frequency group, including the lung (metastatic sites) (12 of 102; 11.8%), pleura (8 of 74; 10.8%), and intrathoracic lymph nodes (12 of 94; 12.8%). The difference in frequency between these two groups was statistically significant (P < 0.05).
CONCLUSIONS: These findings suggest that primary pure SCLC can progress to mixed SC/LC with an increased potential for distant metastasis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8625235     DOI: 10.1002/(SICI)1097-0142(19960115)77:2<278::AID-CNCR9>3.0.CO;2-I

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Elevated RABEX-5 protein expression predicts poor prognosis in combined small cell lung cancer.

Authors:  Fuliang Zhang; Meng Zhang; Guohua Hu; Qiling Cai; Tongbai Xu
Journal:  Tumour Biol       Date:  2015-05-23

2.  High pretreatment serum C-reactive protein level predicts a poor prognosis for combined small-cell lung cancer.

Authors:  Na Shao; Qiling Cai
Journal:  Tumour Biol       Date:  2015-05-31

3.  Long-term survival of a patient with stage IV pulmonary large cell carcinoma achieved by combined-modality therapy: report of a case.

Authors:  S Kobayashi; S Okada; T Hasumi; N Sato; S Fujimura
Journal:  Surg Today       Date:  2000       Impact factor: 2.549

4.  Single primary lung cancer consisting of three cancer cell types (small cell carcinoma, adenocarcinoma, and squamous cell carcinoma) in which each had metastasized to different lymph nodes.

Authors:  Hiroo Shikata; Yoshimichi Ueda; Shuji Tsuchishima; Toshimichi Nonaka; Yoh Watanabe; Junichi Matsubara
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2002-05

5.  High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.

Authors:  N Shao; Q Cai
Journal:  Clin Transl Oncol       Date:  2015-08-05       Impact factor: 3.405

6.  Combined Small Cell Carcinoma of the Lung: Is It a Single Entity?

Authors:  Xiaoliang Zhao; Justine N McCutcheon; Bhaskar Kallakury; Joeffrey J Chahine; Drew Pratt; Mark Raffeld; Yulong Chen; Changli Wang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2017-10-31       Impact factor: 15.609

7.  Multimodality therapy is recommended for limited-stage combined small cell esophageal carcinoma.

Authors:  Huan-Huan Wang; Nicholas G Zaorsky; Mao-Bin Meng; Zhi-Qiang Wu; Xian-Liang Zeng; Bo Jiang; Chao Jiang; Lu-Jun Zhao; Zhi-Yong Yuan; Ping Wang
Journal:  Onco Targets Ther       Date:  2015-02-13       Impact factor: 4.147

8.  Further understanding of an uncommon disease of combined small cell lung cancer: clinical features and prognostic factors of 114 cases.

Authors:  Yu Men; Zhouguang Hui; Jun Liang; Qinfu Feng; Dongfu Chen; Hongxing Zhang; Zefen Xiao; Zongmei Zhou; Weibo Yin; Luhua Wang
Journal:  Chin J Cancer Res       Date:  2016-10       Impact factor: 5.087

9.  [Clinical analysis of 80 patients with combined small-cell lung cancer].

Authors:  Yang Luo; Zhouguang Hui; Lin Yang; Junling Li
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2015-03

10.  Effect of histological subtype and treatment modalities on T1-2 N0-1 small cell lung cancer: A population-based study.

Authors:  Seok-Whan Moon; Jong-Hee Seo; Hyun-Woo Jeon; Mi Hyoung Moon
Journal:  Thorac Cancer       Date:  2019-04-16       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.